Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell luna cancer

Katsuyuki Hotta, Keitaro Matsuo, Katsuyuki Kiura, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose of review: After publication in 1995 of a meta-analysis of adjuvant chemotherapy in the treatment of NSCLC, a number of randomized trials investigated adjuvant chemotherapy using more active chemotherapeutic regimens and larger numbers of accrued patients per trial. This review will focus on recent clinical trials for adjuvant chemotherapy, and will help to interpret the applicability of these results to daily clinical practice. Recent findings: Four large-scale randomized trials that used platinum-based chemotherapy have reported positive results during the last 3 years. These trials included cisplatin-based chemotherapy [the International Adjuvant Lung Cancer (IALT) trial], cisplatin plus vinorelbine [the National Cancer Institute of Canada (NCIC) BR10 trial], and carboplatin plus paclitaxel [the Cancer and Leukemia Group B (CALGB) 9633 trial]. More recently, another adjuvant trial [Adjuvant Navelbine International Trialist Association (ANITA)] was reported, which has added greatly to our understanding of the potential role of adjuvant treatment. Regarding adjuvant UFT (tegafur and uracil) chemotherapy, an individual patient data-based meta-analysis demonstrated its significant effect on survival in selected patients with completely resected non-small-cell lung cancer. Summary: Recent trials indicate a survival benefit of postoperative adjuvant chemotherapy. These findings are anticipated to change the clinical management of patients with completely resectable non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)144-150
Number of pages7
JournalCurrent Opinion in Oncology
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Adjuvant Chemotherapy
Neoplasms
Non-Small Cell Lung Carcinoma
Cisplatin
Meta-Analysis
Tegafur
Drug Therapy
Survival
Uracil
National Cancer Institute (U.S.)
Carboplatin
Paclitaxel
Platinum
Canada
Publications
Lung Neoplasms
Leukemia
Clinical Trials
Therapeutics
vinorelbine

Keywords

  • Adjuvant chemotherapy
  • Cisplatin-based chemotherapy
  • Non-small-cell lung cancer
  • UFT (tegafur and uracil)

ASJC Scopus subject areas

  • Cancer Research

Cite this

Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell luna cancer. / Hotta, Katsuyuki; Matsuo, Keitaro; Kiura, Katsuyuki; Ueoka, Hiroshi; Tanimoto, Mitsune.

In: Current Opinion in Oncology, Vol. 18, No. 2, 03.2006, p. 144-150.

Research output: Contribution to journalArticle

@article{8ffd8cc1138843d28ebaa845a95f9f4d,
title = "Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell luna cancer",
abstract = "Purpose of review: After publication in 1995 of a meta-analysis of adjuvant chemotherapy in the treatment of NSCLC, a number of randomized trials investigated adjuvant chemotherapy using more active chemotherapeutic regimens and larger numbers of accrued patients per trial. This review will focus on recent clinical trials for adjuvant chemotherapy, and will help to interpret the applicability of these results to daily clinical practice. Recent findings: Four large-scale randomized trials that used platinum-based chemotherapy have reported positive results during the last 3 years. These trials included cisplatin-based chemotherapy [the International Adjuvant Lung Cancer (IALT) trial], cisplatin plus vinorelbine [the National Cancer Institute of Canada (NCIC) BR10 trial], and carboplatin plus paclitaxel [the Cancer and Leukemia Group B (CALGB) 9633 trial]. More recently, another adjuvant trial [Adjuvant Navelbine International Trialist Association (ANITA)] was reported, which has added greatly to our understanding of the potential role of adjuvant treatment. Regarding adjuvant UFT (tegafur and uracil) chemotherapy, an individual patient data-based meta-analysis demonstrated its significant effect on survival in selected patients with completely resected non-small-cell lung cancer. Summary: Recent trials indicate a survival benefit of postoperative adjuvant chemotherapy. These findings are anticipated to change the clinical management of patients with completely resectable non-small-cell lung cancer.",
keywords = "Adjuvant chemotherapy, Cisplatin-based chemotherapy, Non-small-cell lung cancer, UFT (tegafur and uracil)",
author = "Katsuyuki Hotta and Keitaro Matsuo and Katsuyuki Kiura and Hiroshi Ueoka and Mitsune Tanimoto",
year = "2006",
month = "3",
doi = "10.1097/01.cco.0000208787.91947.a2",
language = "English",
volume = "18",
pages = "144--150",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell luna cancer

AU - Hotta, Katsuyuki

AU - Matsuo, Keitaro

AU - Kiura, Katsuyuki

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2006/3

Y1 - 2006/3

N2 - Purpose of review: After publication in 1995 of a meta-analysis of adjuvant chemotherapy in the treatment of NSCLC, a number of randomized trials investigated adjuvant chemotherapy using more active chemotherapeutic regimens and larger numbers of accrued patients per trial. This review will focus on recent clinical trials for adjuvant chemotherapy, and will help to interpret the applicability of these results to daily clinical practice. Recent findings: Four large-scale randomized trials that used platinum-based chemotherapy have reported positive results during the last 3 years. These trials included cisplatin-based chemotherapy [the International Adjuvant Lung Cancer (IALT) trial], cisplatin plus vinorelbine [the National Cancer Institute of Canada (NCIC) BR10 trial], and carboplatin plus paclitaxel [the Cancer and Leukemia Group B (CALGB) 9633 trial]. More recently, another adjuvant trial [Adjuvant Navelbine International Trialist Association (ANITA)] was reported, which has added greatly to our understanding of the potential role of adjuvant treatment. Regarding adjuvant UFT (tegafur and uracil) chemotherapy, an individual patient data-based meta-analysis demonstrated its significant effect on survival in selected patients with completely resected non-small-cell lung cancer. Summary: Recent trials indicate a survival benefit of postoperative adjuvant chemotherapy. These findings are anticipated to change the clinical management of patients with completely resectable non-small-cell lung cancer.

AB - Purpose of review: After publication in 1995 of a meta-analysis of adjuvant chemotherapy in the treatment of NSCLC, a number of randomized trials investigated adjuvant chemotherapy using more active chemotherapeutic regimens and larger numbers of accrued patients per trial. This review will focus on recent clinical trials for adjuvant chemotherapy, and will help to interpret the applicability of these results to daily clinical practice. Recent findings: Four large-scale randomized trials that used platinum-based chemotherapy have reported positive results during the last 3 years. These trials included cisplatin-based chemotherapy [the International Adjuvant Lung Cancer (IALT) trial], cisplatin plus vinorelbine [the National Cancer Institute of Canada (NCIC) BR10 trial], and carboplatin plus paclitaxel [the Cancer and Leukemia Group B (CALGB) 9633 trial]. More recently, another adjuvant trial [Adjuvant Navelbine International Trialist Association (ANITA)] was reported, which has added greatly to our understanding of the potential role of adjuvant treatment. Regarding adjuvant UFT (tegafur and uracil) chemotherapy, an individual patient data-based meta-analysis demonstrated its significant effect on survival in selected patients with completely resected non-small-cell lung cancer. Summary: Recent trials indicate a survival benefit of postoperative adjuvant chemotherapy. These findings are anticipated to change the clinical management of patients with completely resectable non-small-cell lung cancer.

KW - Adjuvant chemotherapy

KW - Cisplatin-based chemotherapy

KW - Non-small-cell lung cancer

KW - UFT (tegafur and uracil)

UR - http://www.scopus.com/inward/record.url?scp=33646683043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646683043&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000208787.91947.a2

DO - 10.1097/01.cco.0000208787.91947.a2

M3 - Article

C2 - 16462183

AN - SCOPUS:33646683043

VL - 18

SP - 144

EP - 150

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -